Opinion

Video

Long-Term Follow-Up from CheckMate 9LA at ASCO 2024

Author(s):

Jason Porter, MD

A key opinion leader examines the overall survival data from the CheckMate 9LA study, which evaluated nivolumab plus ipilimumab plus chemotherapy in metastatic non-small cell lung cancer patients, and explores how the long-term follow-up results inform treatment decisions in this setting.

Video content above is prompted by the following questions:

  1. Discuss the data that was presented at the ASCO 2024 on overall survival from the CheckMate 9LA study with the use of nivolumab + ipilimumab + chemotherapy in patients with metastatic NSCLC.
  2. What are your key takeaways from this study?
  3. How do you think the long term follow up data supports decision-making in metastatic NSCLC?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Jorge J. Nieva, MD, Keck School of Medicine
Related Content
IV chemotherapy-Aidman-stock.adobe.com
July 11th 2025

Patients With Advanced NSCLC Face Critical Treatment Gaps

Giuliana Grossi
New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for innovative therapies to improve patient outcomes.
FDA Approved
July 7th 2025

FDA Approves Sunvozertinib in Non–Small Cell Lung Cancer

Julia Bonavitacola
The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Alexander I. Spira, MD, PhD | Image: Virginia Cancer Specialists
July 3rd 2025

COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

Alexander I. Spira, MD, PhD Interview by Mary Caffrey
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic treatment reduces dermatological adverse events in patients with non–small cell lung cancer (NSCLC), enhancing their quality of life during amivantamab therapy.
Joshua K. Sabari, MD | Image: NYU Langone
Published: July 1st 2025 | Updated: June 30th 2025

PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity

Joshua K. Sabari, MD Interview by Mary Caffrey
Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
FDA Approved | Image Credit: © wladimir1804 - stock.adobe.com
June 23rd 2025

FDA Approves Datopotamab Deruxtecan for EGFR-Mutated NSCLC

Pearl Steinzor
The FDA approved datopotamab deruxtecan-dlnk (Datroway; Daiichi Sankyo) for the treatment of locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) after receipt of EGFR-directed therapy and platinum-based chemotherapy.
Opdivo Qvantig packaging | Image credit: BMS
June 18th 2025

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

Mary Caffrey

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo